"The story does not mention any costs of the IUD or other treatments. The story quantifies the benefits of the progestin IUD in several ways. The story accurately notes that the study reported no adverse effects. The study’s authors reported only on adverse effects that were sufficient to require suspension of treatment. The story provides important details about the current study that help the reader evaluate the strength of the evidence. It even emphasizes that the new treatment approach is ""still uNPRoven"". The story does not exaggerate the seriousness or prevalence of uterine cancer and is clear to point out that this treatment is only appropriate for a small subset of cases. The story quotes several independent experts and notes that none had a conflict of interest. The story compares the progestin IUD with systemic hormones and hysterectomy The progestin IUD is clearly available. The story clearly states that the Mirena IUD is not a new idea, but using it to treat early-stage endometrial cancer is relatively novel. Because the story quotes several independent experts, the reader can assume that the story did not rely on a press release as the sole source of information."
IUD Proposed to Treat Uterine Cancer